Technical Analysis for RGLS - Regulus Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
0.82 | -1.57% | -0.01 |
RGLS closed down 1.57 percent on Friday, February 21, 2020, on 28 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Mar 16
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical RGLS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 200 DMA Resistance | Bearish | -1.57% | |
| Outside Day | Range Expansion | -1.57% | |
| Wide Bands | Range Expansion | -1.57% | |
| Oversold Stochastic | Weakness | -1.57% | |
| Wide Bands | Range Expansion | -1.20% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/16/2020
- Sector: Healthcare
- Industry: Biotechnology
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Biopharmaceutical Diseases Genetics Glioblastoma Regulus Therapeutics Hepatocellular Carcinoma RNA Alnylam Pharmaceuticals Hepatitis C Virus Infection Nucleic Acids Atherosclerosis Microrna
Biopharmaceutical Diseases Genetics Glioblastoma Regulus Therapeutics Hepatocellular Carcinoma RNA Alnylam Pharmaceuticals Hepatitis C Virus Infection Nucleic Acids Atherosclerosis Microrna
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.74 |
| 52 Week Low | 0.5 |
| Average Volume | 344,398 |
| 200-Day Moving Average | 0.89 |
| 50-Day Moving Average | 0.97 |
| 20-Day Moving Average | 0.97 |
| 10-Day Moving Average | 0.89 |
| Average True Range | 0.09 |
| ADX | 24.13 |
| +DI | 15.34 |
| -DI | 21.98 |
| Chandelier Exit (Long, 3 ATRs ) | 1.19 |
| Chandelier Exit (Short, 3 ATRs ) | 1.07 |
| Upper Bollinger Band | 1.18 |
| Lower Bollinger Band | 0.77 |
| Percent B (%b) | 0.13 |
| BandWidth | 42.82 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.026 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.95 | ||||
| Resistance 3 (R3) | 0.96 | 0.93 | 0.93 | ||
| Resistance 2 (R2) | 0.93 | 0.90 | 0.93 | 0.92 | |
| Resistance 1 (R1) | 0.88 | 0.88 | 0.90 | 0.86 | 0.91 |
| Pivot Point | 0.84 | 0.84 | 0.86 | 0.84 | 0.84 |
| Support 1 (S1) | 0.79 | 0.81 | 0.82 | 0.78 | 0.73 |
| Support 2 (S2) | 0.76 | 0.79 | 0.75 | 0.72 | |
| Support 3 (S3) | 0.70 | 0.76 | 0.71 | ||
| Support 4 (S4) | 0.69 |
